In the past week, SPRY stock has gone up by 20.50%, with a monthly gain of 26.59% and a quarterly surge of 58.16%. The volatility ratio for the week is 6.94%, and the volatility levels for the last 30 days are 6.20% for ARS Pharmaceuticals Inc The simple moving average for the past 20 days is 14.62% for SPRY’s stock, with a 69.56% simple moving average for the past 200 days.
Is It Worth Investing in ARS Pharmaceuticals Inc (NASDAQ: SPRY) Right Now?
The 36-month beta value for SPRY is also noteworthy at 0.90. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for SPRY is 49.01M, and at present, short sellers hold a 22.64% of that float. The average trading volume of SPRY on October 17, 2024 was 1.09M shares.
SPRY) stock’s latest price update
ARS Pharmaceuticals Inc (NASDAQ: SPRY) has seen a rise in its stock price by 8.47 in relation to its previous close of 15.23. However, the company has experienced a 20.50% gain in its stock price over the last five trading sessions. accesswire.com reported 2024-10-14 that LOS ANGELES, CA / ACCESSWIRE / October 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuticals, Inc. (“ARS” or “the Company”) (NASDAQ:SPRY) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Analysts’ Opinion of SPRY
Raymond James, on the other hand, stated in their research note that they expect to see SPRY reach a price target of $22, previously predicting the price at $18. The rating they have provided for SPRY stocks is “Strong Buy” according to the report published on August 13th, 2024.
Leerink Partners gave a rating of “Outperform” to SPRY, setting the target price at $20 in the report published on August 12th of the current year.
SPRY Trading at 24.08% from the 50-Day Moving Average
After a stumble in the market that brought SPRY to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 0.12% of gains for the given period.
Volatility was left at 6.20%, however, over the last 30 days, the volatility rate increased by 6.94%, as shares surge +17.58% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +68.92% upper at present.
During the last 5 trading sessions, SPRY rose by +20.50%, which changed the moving average for the period of 200-days by +201.46% in comparison to the 20-day moving average, which settled at $14.41. In addition, ARS Pharmaceuticals Inc saw 201.46% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SPRY starting from KATHLEEN D SCOTT, who proposed sale 12,500 shares at the price of $16.00 back on Oct 16 ’24. After this action, KATHLEEN D SCOTT now owns shares of ARS Pharmaceuticals Inc, valued at $200,000 using the latest closing price.
Tanimoto Sarina, the Officer of ARS Pharmaceuticals Inc, proposed sale 300,000 shares at $14.00 during a trade that took place back on Oct 15 ’24, which means that Tanimoto Sarina is holding shares at $4,200,000 based on the most recent closing price.
Stock Fundamentals for SPRY
Current profitability levels for the company are sitting at:
- -120.71 for the present operating margin
- 0.87 for the gross margin
The net margin for ARS Pharmaceuticals Inc stands at -95.37. The total capital return value is set at -0.26. Equity return is now at value -19.34, with -18.66 for asset returns.
Based on ARS Pharmaceuticals Inc (SPRY), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -275.98. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -15.12.
Currently, EBITDA for the company is -67.45 million with net debt to EBITDA at 0.64. When we switch over and look at the enterprise to sales, we see a ratio of 3329.81. The receivables turnover for the company is 0.83for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 32.78.
Conclusion
In summary, ARS Pharmaceuticals Inc (SPRY) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
